TY - JOUR T1 - Latin American Registry of renal involvement in COVID-19 disease. The relevance of assessing proteinuria throughout the clinical course JF - medRxiv DO - 10.1101/2021.05.01.21256389 SP - 2021.05.01.21256389 AU - Raúl Lombardi AU - Alejandro Ferreiro AU - Daniela Ponce AU - Rolando Claure-Del Granado AU - Gustavo Aroca AU - Yanissa Venegas AU - Mariana Pereira AU - Jonathan Chavez-Iñiguez AU - Nelson Rojas AU - Ana Villa AU - Marcos Colombo AU - Cristina Carlino AU - Caio Guimarâes AU - Mauricio Younes-Ibrahim AU - Lilia Maria Rizo AU - Gisselle Guzmán AU - Carlos Varela AU - Guillermo Rosa-Diez AU - Diego Janiques AU - Roger Ayala AU - Galo Coronel AU - Eric Roessler AU - Serena Amor AU - Washington Osorio AU - Natalia Rivas AU - Benedito Pereira AU - Caroline de Azevedo AU - Adriana Flores AU - José Ubillo AU - Julieta Raño AU - Luis Yu AU - Emmanuel A. Burdmann AU - Luis Rodríguez AU - Gianny Galagarza-Gutiérrez AU - Jesús Curitomay-Cruz Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/05/04/2021.05.01.21256389.abstract N2 - The Latin American Society of Nephrology and Hypertension carried out a cohort prospective, multinational registry of patients with kidney impairment associated to COVID-19 in Latin America through open invitation in order to describe the characteristics of the disease in the region. A population of 870 patients from 12 countries were included. Median age was 63 years (54-74), most of patients were male (68.4%) and had comorbidities (87.2%). Acute kidney injury (AKI) was hospital-acquired in 64.7% and non-oliguric in 59.9%. Multiorgan dysfunction syndrome (MODS) due to COVID-19 and volume depletion were the main causes of AKI (59.2% and 35.7% respectively). Kidney replacement therapy was started in 46.2%. Non-recovery of renal function was observed in 65.3%. 71.5% of patients were admitted to ICU and 72.2% underwent mechanical ventilation. Proteinuria at admission was present in 62.4% of patients and proteinuria during hospital-stay occurred in 37.5%. Those patients with proteinuria at admission had higher burden of comorbidities, higher baseline sCr, higher mortality and MODS was severe. On the other hand, patients with de novo proteinuria had lower burden of comorbidities and near normal sCr at admission, but showed adverse course of disease and higher in-mortality. COVID-19 MODS was the main cause of AKI in both groups. All-cause mortality was 57.4%, and it was associated to age, chronic cardiac disease, fluid depletion, COVID-19 MODS, non-recovery of renal function, ICU admission, vasopressors, in-hospital complications and hospital stay. In conclusion, our study contributes to a better knowledge of this condition and highlights the relevance of the detection of proteinuria throughout the clinical course.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://slanh.net/registro-latinoamericano-ira-covid-19/ Funding StatementThe study was supported by the Latin American Society of Nephrology and Hypertension. The Society had no role in the study design data collection and analysis decision to publish or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of the Clinica Los Olivos Cochabamba Bolivia (contact Dr. Esdenka Vega administracion{at}clinicalosolivos.com) approved the study. The informed consent was considered not mandatory by the reference IRB given the observational characteristic of the study. Protocol and forms are available on the study website (https://slanh.net/registro-latinoamericano-ira-covid-19/). Confidentiality of information was appropriately protected by de-identification of data. No personal data of patients was included in the form.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData cannot be shared publicly because of ethical restrictions. In spite cases are appropriately deidentified data are available only on request. Contact via email comiteiraslanh{at}gmail.com Powered https://slanh.net/registro-latinoamericano-ira-covid-19/ ER -